Bionas Hopes Placement of Cell-Physiology Tool At Solvay Will Broaden Market for Nascent Platform | GenomeWeb
German biotech Bionas this week said it has sold one of its Bionas 2500 cell physiology-monitoring tools to Solvay Pharmaceuticals Research Laboratories, which will use it to validate targets in its cardiac and metabolic drug-discovery programs.
The sale helps validate the relatively young instrument’s ability to identify and characterize cell-based targets at a time when Bionas is attempting to expand the list of its potential applications and markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.